Matt O'Brien
Stock Analyst at Piper Sandler
Total Price Targets
49
Stocks Covered
24
Sectors
Healthcare
Most Recent
Feb 20, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Matt O'Brien
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| TNDM | Tandem Diabetes Care, Inc. | $21.00 | $19.34 | +8.6% | 6 | Feb 20, 2026 |
| PEN | Penumbra, Inc. | $374.00 | $325.86 | +14.8% | 4 | Jan 15, 2026 |
| GMED | Globus Medical, Inc. | $115.00 | $91.62 | +25.5% | 2 | Jan 8, 2026 |
| KMTS | Kestra Medical Technologies, Ltd. | $30.00 | $21.67 | +38.4% | 1 | Dec 12, 2025 |
| PRCT | PROCEPT BioRobotics Corporation | $50.00 | $24.27 | +106.0% | 2 | Nov 5, 2025 |
| DXCM | DexCom, Inc. | $75.00 | $61.51 | +21.9% | 4 | Oct 31, 2025 |
| TMDX | TransMedics Group, Inc. | $140.00 | $100.16 | +39.8% | 4 | Oct 30, 2025 |
| BBNX | Beta Bionics, Inc. | $32.00 | $10.32 | +210.1% | 1 | Oct 29, 2025 |
| ITGR | Integer Holdings Corporation | $82.00 | $83.67 | -2.0% | 1 | Oct 24, 2025 |
| KIDS | OrthoPediatrics Corp. | $22.00 | $15.61 | +40.9% | 2 | Oct 10, 2025 |
| HTFL | Heartflow, Inc. Common Stock | $38.00 | $28.82 | +31.9% | 1 | Sep 2, 2025 |
| CARL | Carlsmed, Inc. | $18.00 | $9.57 | +88.1% | 1 | Aug 18, 2025 |
| BSX | Boston Scientific Corporation | $115.00 | $56.91 | +102.1% | 2 | Feb 3, 2025 |
| SYK | Stryker Corporation | $420.00 | $297.71 | +41.1% | 2 | Oct 30, 2024 |
| HUMA | Humacyte, Inc. | $6.00 | $0.85 | +605.9% | 2 | Oct 18, 2024 |
| GKOS | Glaukos Corporation | $140.00 | $142.00 | -1.4% | 2 | Oct 17, 2024 |
| PODD | Insulet Corporation | $285.00 | $175.12 | +62.7% | 3 | Sep 17, 2024 |
| MDT | Medtronic plc | $90.00 | $80.42 | +11.9% | 1 | Aug 21, 2024 |
| ATRC | AtriCure, Inc. | $40.00 | $29.16 | +37.2% | 2 | Jul 31, 2024 |
| TFX | Teleflex Incorporated | $245.00 | $121.84 | +101.1% | 1 | Jul 1, 2024 |
| ZBH | Zimmer Biomet Holdings, Inc. | $115.00 | $83.24 | +38.2% | 2 | Jul 1, 2024 |
| SIBN | SI-BONE, Inc. | $25.00 | $13.21 | +89.3% | 1 | Mar 28, 2024 |
| IART | Integra LifeSciences Holdings Corporation | $50.00 | $10.85 | +360.8% | 1 | Oct 26, 2022 |
| CNMD | CONMED Corporation | $108.00 | $36.67 | +194.5% | 1 | Oct 26, 2022 |
Recent Activity
- Feb 20, 2026— Set$21.00price target onTNDM(Tandem Diabetes Care, Inc.)
- Jan 15, 2026— Set$374.00price target onPEN(Penumbra, Inc.)
- Jan 8, 2026— Set$115.00price target onGMED(Globus Medical, Inc.)
- Dec 12, 2025— Set$30.00price target onKMTS(Kestra Medical Technologies, Ltd.)
- Nov 5, 2025— Set$50.00price target onPRCT(PROCEPT BioRobotics Corporation)
- Oct 31, 2025— Set$75.00price target onDXCM(DexCom, Inc.)
- Oct 30, 2025— Set$140.00price target onTMDX(TransMedics Group, Inc.)
- Oct 29, 2025— Set$32.00price target onBBNX(Beta Bionics, Inc.)
- Oct 24, 2025— Set$82.00price target onITGR(Integer Holdings Corporation)
- Oct 21, 2025— Set$100.00price target onDXCM(DexCom, Inc.)
- Oct 10, 2025— Set$22.00price target onKIDS(OrthoPediatrics Corp.)
- Sep 2, 2025— Set$38.00price target onHTFL(Heartflow, Inc. Common Stock)
- Aug 18, 2025— Set$18.00price target onCARL(Carlsmed, Inc.)
- Aug 7, 2025— Set$14.00price target onTNDM(Tandem Diabetes Care, Inc.)
- Feb 3, 2025— Set$115.00price target onBSX(Boston Scientific Corporation)
- Dec 11, 2024— Set$90.00price target onTMDX(TransMedics Group, Inc.)
- Oct 31, 2024— Set$235.00price target onPEN(Penumbra, Inc.)
- Oct 30, 2024— Set$420.00price target onSYK(Stryker Corporation)
- Oct 18, 2024— Set$6.00price target onHUMA(Humacyte, Inc.)
- Oct 18, 2024— Set$225.00price target onPEN(Penumbra, Inc.)
Frequently Asked Questions
Who is Matt O'Brien?
Matt O'Brien is a stock analyst at Piper Sandler covering 24 stocks primarily in Healthcare. They have issued 49 price targets since May 3, 2022.
What stocks does Matt O'Brien cover?
Matt O'Brien currently covers 24 stocks, including TNDM, PEN, DXCM, TMDX, PODD.
What is Matt O'Brien's latest price target?
Matt O'Brien's most recent price target was $21.00 on TNDM (Tandem Diabetes Care, Inc.), set on Feb 20, 2026.
What is Matt O'Brien's highest price target?
Matt O'Brien's highest issued price target is $420.00 on SYK, set on Oct 30, 2024.
More Analysts at Piper Sandler
Coverage based on publicly published price targets. Not investment advice.